Automated Test Detects HIV Antibodies

A fully automated diagnostic immunoassay determines whether antibodies to the human immunodeficiency virus (HIV) are present in human serum and plasma.

Bayer HealthCare Diagnostics Division (Tarrytown, New York, USA) a member of the Bayer Group, today announced that the fully-automated test called EHIV (human immunodeficiency virus, enhanced), has received U.S. Food and Drug Administration (FDA) approval for use on the Advia Centaur immunoassay system. Advia Centaur EHIV is a fully-automated test that contains a range of recombinant proteins and sub-type O peptide for the detection of antibodies to HIV-1, HIV- 2, and sub-type O peptide. This meets the worldwide healthcare standards for detecting all known types of HIV infection.

The EHIV fully-automated testing process provides advanced features such as automatic algorithm processing, cascade reflex testing, user-defined panels, and automatic repeats of critical samples. Combined with security and verification features, such as the use of sample tips and assay verification processes, the Advia Centaur EHIV allows laboratories to increase their HIV testing productivity with enhanced confidence in their HIV results.

In addition to testing for infectious diseases, the Advia Centaur immunoassay system provides testing for a broad range of conditions, including cancer, cardiovascular diseases, fertility, anemia, thyroid diseases, allergy, metabolic diseases, and therapeutic drug monitoring.



Related Links:
Bayer HealthCare Diagnostics